NIPH Clinical Trials Search

A research study comparing how well different doses of the medicine NNC0662-0419 lower blood sugar in people with type 2 diabetes

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Type 2 diabetes
Date of first enrollment	17/04/2026
Target sample size	25
Countries of recruitment	United States,Japan,Croatia,Japan,Hungary,Japan,Poland,Japan,Portugal,Japan,Slovakia,Japan,South Korea,Japan,Spain,Japan,Thailand,Japan
Study type	Interventional
Intervention(s)	Drug: NNC0662-0419 NNC0662-0419 will be administered subcutaneously. Drug: Semaglutide Semaglutide will be administered subcutaneously. Drug: Placebo Placebo will be administered subcutaneously.

Outcome(s)

Primary Outcome	-Change in glycated haemoglobin (HbA1c) (week 16) [Time Frame: From baseline (week 0) to week 16]-Measured as percentage-point (%-point). -Change in HbA1c (week 28) [Time Frame: From baseline (week 0) to week 28]-Measured as %-point. -Change in HbA1c (week 40) [Time Frame: From baseline (week 0) to week 40]-Measured as %-point.
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	< 75age old
Gender	Both
Include criteria	-Male or female (sex at birth). -Age 18-75 years (both inclusive) at the time of signing the informed consent. -Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole [mmol/mol]) (both inclusive) as assessed by central laboratory at screening. -Willingness to obtain a high weight loss (greater than [>] 25% of weight at baseline).
Exclude criteria	-Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. -Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. -Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.